Physician profile
Clark Philogene
NPI 1558462044
$6,807.35
in general payments reported to CMS, 2019-2025
45 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $835 · 2021: $1,070 · 2022: $980 · 2023: $1,011 · 2024: $942 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,452.11 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $695.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $535.36 | 2019-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.84 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $457.81 | 2019-2023 | |
| Pfizer INC. | $421.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $296.61 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $253.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $225.60 | 2019-2022 | |
| Lilly USA, LLC | $213.03 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $209.36 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $199.77 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $181.14 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $97.54 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Redhill Biopharma INC. | $93.50 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clark Philogene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.